AKBA•benzinga•
Akebia Therapeutics Announces Publication In JASN Of U.S. And Non-U.S. Subgroup Analyses From Vadadustat Global Phase 3 Trials, Showing Comparable Safety And Efficacy In Dialysis-Dependent CKD Patients And Highlighting Elevated MACE Risk In U.S. Non–Dialy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 4, 2025 by benzinga